Ampio Pharmaceuticals, Inc. (AMPE) financial statements (2020 and earlier)

Company profile

Business Address 373 INVERNESS PARKWAY
ENGLEWOOD, CO 80112
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8885275026
Cash and cash equivalents8885275026
Short-term investments  00   
Prepaid expense1   210
Derivative instruments and hedges, assets  00   
Other current assets    2  
Other undisclosed current assets1000(2)0 
Total current assets:10885295126
Noncurrent Assets
Property, plant and equipment56789101
Intangible assets, net (including goodwill)    381
Goodwill    0  
Intangible assets, net (excluding goodwill)    381
Regulated entity, other noncurrent assets    0  
Deposits noncurrent assets 000000
Other undisclosed noncurrent assets1  0818
Total noncurrent assets:6678211910
TOTAL ASSETS:16141514507036
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2131332
Accounts payable1   332
Accrued liabilities2      
Other undisclosed accounts payable and accrued liabilities(0)131   
Deferred rent credit 0
Due to related parties    1  
Deferred revenue and credits00000
Other undisclosed current liabilities0 11101
Total current liabilities:2142642
Noncurrent Liabilities
Long-term debt and lease obligation    5  
Long-term debt, excluding current maturities    5  
Liabilities, other than long-term debt87465210
Deferred revenue and credits11110
Deferred rent credit 0
Business combination, contingent consideration, liability    1 
Derivative instruments and hedges, liabilities874540  
Other undisclosed noncurrent liabilities1   0  
Total noncurrent liabilities:97465710
Total liabilities:1294971253
Stockholders' equity
Stockholders' equity attributable to parent, including:45347376633
Common stock0000000
Additional paid in capital18817617116017116897
Accumulated deficit(184)(171)(205)(153)(134)(102) 
Other undisclosed stockholders' equity attributable to parent  68(0)(0)(0)(64)
Stockholders' equity attributable to noncontrolling interest    1(1)0
Other undisclosed stockholders' equity  (68)    
Total stockholders' equity:45(34)7386533
TOTAL LIABILITIES AND EQUITY:16141514507036

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues    100
Revenue, net  100
Cost of revenue
(Cost of Goods and Services Sold)
    (0)  
Gross profit:    100
Operating expenses(14)(11)(16)(17)(34)(39)(24)
Other operating income, net 45     
Other undisclosed operating income45   0  
Operating income (loss):3134(16)(17)(33)(39)(24)
Nonoperating income (expense)(42) (36)(2)(0)0(1)
Investment income, nonoperating(42) (36)(1)(0)0(1)
Interest and debt expense    (0)  
Income (loss) from continuing operations before income taxes:(11)34(52)(19)(34)(39)(25)
Income tax benefit     5 
Income (loss) before gain (loss) on sale of properties:(11)34(52)(19)(34)(34)(25)
Other undisclosed net income (loss)    0(5)1
Net income (loss):(11)34(52)(19)(34)(39)(24)
Net income attributable to noncontrolling interest    211
Other undisclosed net loss attributable to parent      (1)
Net income (loss) attributable to parent:(11)34(52)(19)(32)(38)(25)
Preferred stock dividends and other adjustments(4)      
Net income (loss) available to common stockholders, diluted:(15)34(52)(19)(32)(38)(25)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(11)34(52)(19)(34)(39)(24)
Comprehensive income (loss):(11)34(52)(19)(34)(39)(24)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest    21(1)
Comprehensive income (loss), net of tax, attributable to parent:(11)34(52)(19)(32)(38)(25)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: